| Drug Name |
Hydroxyurea |
| Drug ID |
BADD_D01110 |
| Description |
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. |
| Indications and Usage |
For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia. |
| Marketing Status |
approved |
| ATC Code |
L01XX05 |
| DrugBank ID |
DB01005
|
| KEGG ID |
D00341
|
| MeSH ID |
D006918
|
| PubChem ID |
3657
|
| TTD Drug ID |
D07CWD
|
| NDC Product Code |
0904-6939; 35369-0006; 49452-3650; 55154-7143; 61269-403; 68084-284; 70518-3615; 51927-0072; 0555-0882; 55154-3554; 69315-164; 38779-1354; 42291-321; 71770-105; 49884-724; 17337-0023; 0003-6335; 0003-6337; 60429-265; 61269-835; 70518-0916; 55512-0003; 61269-402; 71770-120; 0003-0830; 51552-0851; 62049-135; 0003-6336; 61269-404; 10135-702; 71052-323; 17337-0022 |
| UNII |
X6Q56QN5QC
|
| Synonyms |
Hydroxyurea | Hydroxycarbamid | Oncocarbide | Hydrea |
